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Objectives: To measure the health-related quality of life (HRQoL) of multiple sclerosis (MS) 
patients and their caregivers, and to assess which factors can best describe HRQoL.
Methods: A cross-sectional multicenter study of nine hospitals enrolled MS patients and their 
caregivers who attended outpatient clinics consecutively. The instruments used were the SF-36 
for patients and the SF-12 and GHQ-12 for caregivers. Classification and regression tree analysis 
was used to analyze the explanatory factors of HRQoL.
Results: A total of 705 patients (mean age 40.4 years, median Expanded Disability Status Scale 
2.5, 77.8% with relapsing-remitting MS) and 551 caregivers (mean age 45.4 years) participated 
in the study. MS patients had significantly lower HRQoL than in the general population (physical 
SF-36: 39.9; 95% confidence interval [CI]: 39.1–40.6; mental SF-36: 44.4; 95% CI: 43.5–45.3). 
Caregivers also presented lower HRQoL than general population, especially in its mental 
domain (mental SF-12: 46.4; 95% CI: 45.5–47.3). Moreover, according to GHQ-12, 27% of 
caregivers presented probable psychological distress. Disability and co-morbidity in patients, 
and co-morbidity and employment status in caregivers, were the most important explanatory 
factors of their HRQoL.
Conclusions: Not only the HRQoL of patients with MS, but also that of their caregivers, is 
indeed notably affected. Caregivers’ HRQoL is close to population of chronic illness even that 
the patients sample has a mild clinical severity and that caregiving role is a usual task in the 
study context.
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Background
Multiple sclerosis (MS) is a chronic progressive neurological disease characterized by 
central nervous system demyelization and axonal disruption.1 Its onset is usually in early 
adulthood and affects 2.5 million persons worldwide.2 MS causes many disabilities 
such as spastic paresis, ataxia of gait and the extremities, central visual loss, double 
vision, paresthesia, dysarthria, bladder and sexual disturbances, and fatigue.3
The US Institute of Medicine elaborated a report, commissioned by the National 
Multiple Sclerosis Society, evaluating research needs in the MS field and their 
perspectives for the future.4 According to this report, in spite of the great deal of 
research effort devoted to this illness, there are still unresolved questions, and one 
of these is: How can we help persons with MS to adapt to their illness, and live their 
lives as fully as possible? Our challenge is to meaningfully contribute to the literature 
on this issue because many factors can condition the quality of life of people with 
MS, and there is a need to determine what these factors are. Deeper knowledge would Patient Preference and Adherence 2009:3 312
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make it possible to develop and enhance interventions able to 
maintain or improve these patients’ quality of life.
Research in quality of life is part of a movement towards 
patient-centered care, in which the patient’s perspective is 
taken as the principal reference point, since health-related 
quality of life (HRQoL) instruments can reveal aspects of 
illness that are not reflected by standard clinical instruments, 
and they can measure results that are of major concern to 
the patient. For the sake of the present study, HRQoL is 
considered that of perceived overall health, incorporating 
physical, mental, and social elements.5 Some studies 
emphasize the value of HRQoL to predict changes in 
disability status over a substantial period of time in patients 
with MS.6 In recent years, different studies have shown the 
impact of MS on HRQoL, not only in patients,7,8 but also in 
their caregivers.9
MS-related disabilities have been reported as probable 
explanations for this impact. Thus, physical disability, fatigue, 
chronic pain, sexual disturbance and bladder dysfunction 
have shown their impact in HRQoL.10–14 However, other 
factors besides disabilities can probably affect HRQoL, 
and to know amongst them which ones better explain the 
HRQoL of MS patients could help when setting priorities 
in treatment programs. Therefore, the aim of the present 
multicenter study was to measure the HRQoL of MS patients 
and their family caregivers, as well as to analyze the most 
important associations between HRQoL and different clinical 
and sociodemographic characteristics not only of patients, 
but also of their caregivers, from whose these factors have 
been poorly studied.
Seven million people inhabit the Catalonia region in 
the northeast of Spain, which is located in a low-latitude 
climate zone traditionally considered a low prevalence area 
for MS. A study of HRQoL in this region is valuable because 
a rising prevalence of MS has been reported (being as high 
as 58/100,000 inhabitants) and the disease seems to have a 
relatively milder clinical severity.15 In addition, family social 
support is more available in Mediterranean countries than 
in other cultures.16 It would, therefore, be also interesting 
to see whether, given these characteristics, HRQoL of MS 
patients and their caregivers is similar to the one reported 
in other regions.
Methods
A cross-sectional multicenter study was designed, 
incorporating nine hospitals from Catalonia. The subjects 
of the study were MS patients and their caregivers who 
presented consecutively at outpatient clinics in the 
participating hospitals. The sample size was calculated to 
be representative for the Catalan MS population bearing in 
mind data from prevalence studies carried out in the area,15 
assuming a confidence level of 95% and an accuracy level 
that would only tolerate a difference of 0.035. The sample 
size was estimated at 638 patients but, assuming a 10% level 
of missing data, we aimed to recruit 702 patients and their 
family caregivers.
The inclusion criteria for patients were as follows: 1) having 
a definite diagnosis of MS, according to Poser’s criteria 
(relapsing-remitting MS),17 or having MS defined clinically 
or according to laboratory tests, as well as evidence of 
progressive neurological disability (progressive MS);18 and 
2) being able to understand the questions on the HRQoL 
questionnaires. Patients were excluded if they were in an 
acute phase or a relapse of the illness, were suffering severe 
illness not related to MS or drug dependency, and/or were 
taking part in clinical trials. As to the family caregivers, the 
selection criteria were: 1) that they lived with the patient and 
took care of him or her; that is, caregiver fulfilled the needs 
of the patient whatever these needs were (from the minimum 
ones as helping with the medication, to the maximum ones as 
providing help with activities of daily living; 2) voluntarily 
caregiving; and 3) being able to understand the questions on 
the HRQoL questionnaires.
The 36-question Short Form Health Survey (SF-36) was 
used to assess patients’ HRQoL since no specific instrument 
for MS had been validated in Catalan or Spanish at the time 
of the study.19 The 12-item Short Form Health Survey (SF-12) 
was used for assessing the family caregivers’ HRQoL,20 and 
the short-form General Health Questionnaire (GHQ-12) 
was used for assessing their psychological distress.21 Both 
the SF-36 and SF-1222 as well as the GHQ-1223,24 have 
been adapted and validated for both Catalan and Spanish 
languages.
Since the questionnaires had to be answered during the 
outpatient visit, clinicians considered that questionnaires 
should take less than ten minutes for a respondent to 
complete. In addition, taking into account that our underlying 
hypothesis was that family caregivers would show an affected 
mental domain in HRQoL, we decided to assess the psycho-
logical distress as well (by means of the GHQ-12). Therefore, 
for the sake of brevity, the SF-12 instead of SF-36 was used 
for assessing the family caregivers’ HRQoL.
The generic instruments for measuring HRQoL – the 
SF-36 and SF-12 –  were designed by the Medical Outcomes 
Trust, and indicate the subject’s state on a scale of 0 (lowest) 
to 100 (highest). The SF-36 contains 36 questions distributed Patient Preference and Adherence 2009:3 313
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over eight dimensions, covering two areas: functional state 
and emotional well-being. Although this questionnaire does 
not generate a global index, it does calculate two summary 
scales: the physical and mental domains of HRQoL. 
The SF-12 comprises a subset of 12 questions from the 
SF-36, including one or two items from each of its eight 
dimensions. In calculating the mental and physical health 
summary scales on the SF-36 and SF-12, local population 
norms (Spanish, in the present paper) were taken into con-
sideration as previously derived.25 In norm-based scoring, 
each scale is scored to have same average (50) and the same 
standard deviation (10 points). Without referring to norms, it 
is clear that anytime a scale score is below 50, health status 
is below average, and each point is one-tenth of a standard 
deviation.26,27 If 95% confidence intervals (CI) are calculated 
and they do not include the value of 50, this means that 
differences between the reference norm (general population) 
and the study sample are statistically significant.
The GHQ-12 is the brief version (12 questions) of the 
General Health Questionnaire (60 questions) designed by 
Goldberg to detect psychological distress in the general 
population as well as in outpatients and primary care 
patients.21 The GHQ-12 identifies probable psychological 
distress (although indicating neither the type of distress nor 
its severity) based on a certain cut-off point which, in this 
case, was 3 points.
A specific form with clinical and sociodemographic 
factors was filled in by the neurologist or the nurse during 
the outpatient visit. These factors comprise the independent 
variables of the study that are described below.
The study variables used were as follows:
a)  As dependent variables, the scores obtained on the 
HRQoL scales (SF-36 in patients and SF-12 in family 
caregivers).
b)  As independent variables, the different clinical and 
sociodemographic factors collected. The latter were: 
age, sex, marital status, number of children, level of 
studies and employment situation for all subjects, as 
well as relationship with the patient and length of time 
sharing living quarters, for the family caregiver. As 
clinical variables, in the case of the patient, we took into 
account the type of MS, number of relapses per year, level 
of physical disability (Kurtzke’s Expanded Disability 
Status Scale [EDSS] score),28 year of diagnosis, current 
treatment, whether they follow rehabilitation therapy, 
and chronic co-morbidity according to a closed list of 
chronic illnesses included in the Catalan Health Survey;29 
in the case of the family caregiver, we recorded chronic 
morbidity according to the same list used for the patients, 
psychopharmacological medications taken, whether they 
had undergone psychotherapy, and the hours spent daily 
in physically helping the patient.
All of these items were introduced into a database, 
checking the entries and eliminating possible duplicate cases. 
For the statistical analysis of the data, we first carried out a 
descriptive exploration of the sociodemographic, clinical, 
and HRQoL characteristics of the patients and their family 
caregivers. The assessment of possible factors explaining 
the HRQoL of patients and their family caregivers was 
conducted using multivariate analysis, seeking a model able 
to explain dependent variables from the SF-36 and SF-12 
based on a series of factors or independent variables. This 
analysis was carried out using classification and regression 
tree analysis (CART).30 By dividing the independent variables 
into subgroups, this analysis makes it possible to obtain 
information for selecting, from amongst all of them, the 
one having the maximum capacity to explain the values of 
the dependent variable, ie, one that explains the most variance 
in the dependent variable. The independent variables were 
broken up into groups with the idea of minimizing intragroup 
variance and maximizing intergroup variance. In the analysis, 
the Chi-square test was used and, in order to control for 
the multiple test comparison, Bonferroni’s correction was 
applied. At the end of this process, a “tree” was obtained, 
ranking the potential explanatory variables from greatest 
to least percentage of explanation of the variance of the 
dependent variable.
The model’s validation was carried out by breaking 
down the database so that it randomly generated a sample 
including 60% of the cases, and then estimating accuracy 
by calculating the proportion of correct classifications that 
could be obtained by applying this model to the cases in the 
random sample.
The statistical analysis was conducted with SPSS software 
(version 15.0; SPSS Inc., Chicago, IL, USA) and Knowledge 
Seeker 3.10 (Angoss Software, Toronto, ON, Canada).
Results
During the three years of the study’s data-gathering phase, 
information was obtained on 705 patients with MS and 
551 family caregivers from nine hospitals in Catalonia 
(northeastern Spain). The distribution of number of patients 
(np) and caregivers (nc) by center was: Taulí Sabadell (np = 33; 
nc = 33); Trueta Girona (np = 53; nc = 50); Clínic Barcelona 
(np = 67; nc = 46); Vall d’Hebron Barcelona (np = 198; nc = 120); 
Mútua de Terrassa (np = 59; nc = 28); Vic (np = 32; nc = 32); Patient Preference and Adherence 2009:3 314
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Bellvitge Barcelona (np = 129; nc = 120); Germans Trias 
Badalona (np = 49; nc = 49); and Fundació Esclerosi Múltiple 
(np = 85; nc = 73). There were no statistically significant 
differences between centers regarding patients’ age, gender, 
EDSS, and duration of MS.
Table 1 presents the sociodemographic characteristics 
of both patients with MS and their caregivers. As to clinical 
characteristics, we found that a majority of patients (77.8%) 
suffered relapsing-remitting MS, with an average physical 
disability (median), according to EDSS criteria, of 2.5, and 
at least one co-morbid chronic condition (70.8%). These 
patients were mainly being treated with Interferon-beta 
(62.5%), and 29% were in a rehabilitation program. As to 
their family caregivers, 67.8% reported suffering from some 
kind of chronic illness, and 15% of these family members 
were taking psychopharmaceutical medication, receiving 
psychotherapeutic treatment, or both.
The results of the HRQoL assessment of patients with 
MS, according to the eight dimensions on the SF-36, were 
lower in all of these dimensions when compared with the 
normative data for the general population, even at early 
stages of physical disability measured by EDSS (Table 2). 
The physical health summary scale (physical HRQoL) and 
the mental health summary scale (mental HRQoL) of both 
patients and caregivers are shown in Table 3 and Figure 1. 
These results also showed that the MS patients had a lower 
HRQoL than the general population and, as to their family 
caregivers, we found that they also perceived their HRQoL 
(according to the SF-12) to be worse than that of the general 
population, specifically in its mental component. According 
to the GHQ-12 results, 27% of this sample met criteria for 
probable psychological distress (Table 4).
Looking at the results stratified by gender, we found that 
women had a lower mental HRQoL than men, both in the 
MS patients sample (43.7; 95% CI: 42.6–44.8 versus 45.7; 
95% CI: 44.1–47.2) and in that of their family caregivers 
(44.4; 95% CI: 43–45.8 versus 48.4; 95% CI: 47.2–49.6). 
In addition, the proportion of probable cases of psychological 
distress amongst women was significantly higher than in men 
(Table 4). The differences in the physical HRQoL, when 
examined by gender, were not statistically significant in either 
of the sample groups.
In the multivariate analysis, a CART model was designed 
according to each dependent variable (SF-36 and SF-12 
physical and mental health summary scales) in order to 
determine which were the explanatory factors of the HRQoL 
of patients with MS and their family caregivers. We found that 
the factors explaining the physical HRQoL in MS patients 
were the level of physical disability generated by the illness, 
and chronic co-morbidity (Figure 1). A third factor that 
explained the level of perceived physical HRQoL, within 
the group having moderate disability and some co-morbid 
condition, was the MS treatment they were receiving, with 
a higher proportion of patients (93%) having a physical 
HRQoL lower than the general population among those who 
were taking no base treatment. The estimated accuracy of this 
model was 73%. Regarding the mental HRQoL in patients 
with MS, self-reported anxiety had the most influence on a 
poor HRQoL (62%), followed by self-reported depression; 
amongst those in the group that did not report suffer from 
anxiety, the type of MS was the second most important 
explanatory factor, with a primary progressive pattern being 
related to a better mental HRQoL. The model’s estimated 
accuracy was 61%.
As an explanatory factor of the SF-12 HRQoL physical 
health summary scale in family caregivers, employment 
status was generally the most striking; specifically, finding 
oneself in a situation of long-term illness explained a lower 
physical HRQoL. This model’s estimated accuracy was 58%. 
Regarding the SF-12 HRQoL mental health summary scale in 
family caregivers, the most important explanatory factor for 
a mental HRQoL lower than that of the general population 
was self-reporting of suffering from anxiety (Figure 2). 
Moreover, among those who reported suffering from anxiety, 
the hours devoted to helping the patient also influenced their 
HRQoL; the more hours of dedication, the lower the mental 
HRQoL. Finally, other secondary explanatory factors for 
mental HRQoL were self-reported depression, or the kind 
of relationship with the patient; thus, the mental HRQoL 
was lower in mothers or children. The model’s estimated 
accuracy was 60%.
Discussion
The present study has shown that MS patients’ HRQoL is 
lower than that of the general population, as results from 
previous studies in other regions also showed.7,8,31–33 MS not 
only affects those who suffer from it directly; their caregivers 
also presented a HRQoL lower than that of the general 
population, being especially true where the mental HRQoL 
is concerned. To this we should add that the mental HRQoL 
of the family caregivers was closer to that of the population 
with chronic illness or subclinical depression than that of the 
general population.34,35 These results are consistent with the 
findings of other studies on the impact of caring for an MS 
patient on psychological well-being.9,36–38 It should also be 
pointed out that a poor caregiver HRQoL finding is indeed Patient Preference and Adherence 2009:3 315
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Table 1 sociodemographics and clinical characteristics of the sample
Patients n = 705 Family caregivers n = 551
sex (female) 459 (65%) 280 (50.8%)
Age (years): mean ± sD (range) 40.4 ± 11.6 (16–73) 45.4 ± 12.8 (13–78)
Years living with the patient: mean ± sD – 11.2 ± 9.7
hours/day caring for the patient: mean ± sD – 3.25 ± 5.7
Marital status
  single 150 (21.3%) 49 (8.9%)
  separated or divorced 50 (7.1%) 9 (1.6%)
  Married or with partner 484 (68.7%) 471 (85.5%)
  Widowed 21 (3%) 22 (4%)
Tie to patient
  spouse or partner – 358 (65.9%)
  son or daughter 44 (8.1%)
  Mother 98 (18%)
  Father 21 (3.9%)
  Other 22 (4.1%)
  subjects with children 463 (65.7%) 441 (80%)
  number of children – Mean (range) 2 (0–6) 2 (0–8)
Educational level
  No school certificate 5 (0.8%) 11 (2%)
  Primary school 319 (45.2%) 286 (52%)
  secondary school 240 (40%) 173 (31.5%)
  University 137 (22.8%) 80 (14.5%)
Employment situation
  self-employed 59 (8.4%) 91 (16.8%)
  Works for an employer 167 (23.7%) 242 (44.6%)
  Unemployed 38 (5.4%) 30 (5.5%)
  Long-term illness 236 (33.5%) 18 (3.3%)
  short-term sick leave 35 (4.9%) 6 (1.1%)
  housewife 122 (17.3%) 36 (6.6%)
  student 20 (2.8%) 108 (19.9%)
  Other 10 (1.4%) 11 (2%)
Housing
  Lives alone 43 (6.1%) –
  institutionalized 5 (0.7%)
  Lives with spouse and/or children 511 (72.8%)
  Lives with parents 133 (18.9%)
  Other 10 (1.4%)
MS pattern
  Relapsing-remitting 477 (77.8%)
  Primary progressive 68 (11.1%)
  secondary progressive 68 (11.1%)
Disability: median EDSS 2.5
Duration of MS
  Mean (sD) 6.33 (5.40)
  Range 0–34
(Continued)Patient Preference and Adherence 2009:3 316
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more relevant given that in our study we considered any 
kind of caregiving, including minimal tasks as preparing 
medication, that our patients sample had a relatively mild 
clinical severity (median EDSS 2.5), and that caregiving role 
is a usual task in our culture.
The observed patients’ HRQoL scores on the eight SF-36 
dimensions were found to be within the range of scores 
reported in other countries where analogous studies have 
been carried out, including Canada (n = 198),39 England 
(n = 929),40 France (n = 121),41 Israel (n = 214),42 Italy 
(n = 445),43 Norway (n = 194),44 Portugal (n = 23),45 The 
Netherlands (n = 56),46 and the United States (n = 201).47 By 
SF-36 dimensions, the following ones are the HRQoL score 
ranges (mean and standard deviation when stated) from the 
above-mentioned previous studies:
•  Physical functioning: 29.2 (29.7)–59.9 (25.9)
•  Role limitations – physical: 26.7–60.1 (39.5)
•  Bodily pain: 49.2 (7.7)–77.1 (24.4)
•  General health: 43.2 (17.8)–59.9 (22.6)
•  Vitality: 34.7 (22.2)–53.5 (?)
•  Social functioning: 56.5 (30.3)–78.5 (24.2)
•  Role limitations – emotional: 46.6–89.7 (25.2)
•  Mental health: 55.2 (18.1)–78.6 (15.5)
In addition, upon comparing the HRQoL profiles stratified 
by level of physical disability (EDSS), as was done in other 
four studies besides ours,39,42,44,48 it can be seen that the 
profiles are similar. However, although these studies were 
consistent in showing the difference between the HRQoL of 
MS patients compared with the general population, none of 
them, including ours, repeated the results of the Canadian 
Table 1 (Continued)
Patients n = 705 Family caregivers n = 551
Co-morbidity
  none 181 (29.2%) 176 (32.2%)
  One 143 (23.1%) 142 (26.0%)
  Two 108 (17.5%) 87 (15.9%)
  Three 83 (13.4%) 56 (10.2%)
  Four 51 (8.2%) 40 (7.3%)
  Five or more 53 (8.6%) 46 (8.4%)
  Most frequent co-morbidity Anxiety (25.3%) Arthrosis or arthritis (19.1%)
Notes: Patients’ missing values:  age (6); educational level (4);  housing (3);  Ms pattern (92); disability–eDss (106); years with Ms (88); co-morbidity (86). Family caregivers’ missing 
values:  age (10); years living with patient (32);  hours/day physically assisting the patient (94); tie to patient (8); subjects with children (4); educational level (1);  employment 
situation (9); co-morbidity (4).
Abbreviations: eDss, expanded Disability status scale; sD, standard deviation.
Table 2 HRQoL of patients with MS, total sample, and stratified by EDSS level
Mean (SD)        
Total sample  
(n = 705)
EDDS  3  
(n = 315)
EDSS 3–6  
(n = 222)
EDSS  6  
(n = 62)
Normative sample 
(n = 9151)*
SF–36 dimension
  Physical functioning 52.41 (32.16) 74.53 (22.98) 43.69 (23.87) 8.40 (14.64) 84.7 (24.0)
  Role limitations – Physical 45.86 (42.69) 59.02 (42.57) 36.66 (39.76) 38.71 (38.86) 83.2 (35.2)
  Bodily pain 69.01 (29.08) 71.23 (27.76) 64.62 (29.65) 65.35 (32.54) 79 (27.9)
  general health 49.69 (20.28) 55.51 (20.72) 43.92 (17.88) 43.78 (19.55) 68.3 (22.3)
  Vitality 46.49 (23.44) 53.67 (22.57) 38.97 (22.05) 43.10 (22.58) 66.9 (22.1)
  social functioning 71.02 (27.82) 78.61 (23.76) 66.65 (27.74) 56.75 (34.84) 90.1 (20.0)
  Role limitations – emotional 67.87 (41.98) 72.93 (39.16) 64.34 (43.49) 70.97 (42.46) 88.6 (88.6)
  Mental health 61.79 (21.32) 65.08 (20.41) 59.71 (21.96) 60.79 (22.36) 73.3 (20.1)
Notes: eDss categories: eDss  3 (mild; from normal neurological results to minimal disability), eDss 3–6 (moderate; fair disability but retaining ambulation), eDss  6 
(severe; from requiring important assistance for ambulation to restricted to chair or bed).   As stated in Table 1, there were 106 missing values regarding eDss levels. *From 
Alonso and colleagues.25
Abbreviations: eDss, expanded Disability status scale; sD, standard deviation.Patient Preference and Adherence 2009:3 317
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study, in which very poor HRQoL was found from the lowest 
levels of physical disability (EDSS  3). Still, it is worth 
bearing in mind that the Canadian study, unlike the others, 
had taking Interferon-beta as one of its exclusion criteria. 
Actually, a multicenter study in Germany (n = 1157) showed 
that HRQoL was considerably lower in early stages of MS 
compared with the general population but was improved, 
with statistically significant results, after treatment initiation 
with Interferon-beta.49
The male-to-female ratio of patients in our study (1:1.9; 
derived from Table 1 data) practically coincides with the 
distribution in our area overall (1:2; 1:1.8).15,50 Regarding 
gender distribution of family caregivers, looking at Table 1, 
our most striking finding was that they were practically 
50:50, despite the fact that the most frequent tie with patients 
was a spousal relationship (70%) and the majority of the 
patients were women (65%). Therefore, statistically, most 
of the family caregivers should have been men, but that was 
not the case; indeed, 93% of the male patients were cared 
for by a woman, but not vice-versa, because only 72% of 
the women had a male caregiver. These findings agree with 
other study in southern Europe51 and contrast with those of a 
study of MS patients’ families in New Zealand, where most 
of the caregivers were men, even though in this country the 
caregiver role was not a traditionally male one, either.52
The gender differences in HRQoL found in the present 
study also appear in the general population.25 However, 
these differences, both in patients and caregivers, were 
only statistically significant for the mental health domain of 
the HRQoL. In fact, amongst caregivers, the proportion of 
psychological distress was higher in women (29.5%) than 
in men (24%). Such a difference is also found in the general 
population, although it is less marked (18.9% in women and 
15.8% in men), and with 9.5% less possible cases of mental 
disorder, altogether.23
The CART multivariate analysis models used have shown 
that the potential explanatory factors for a lower HRQoL 
in patients with MS are the physical disability generated 
by the illness itself and co-morbidity. Amongst the family 
caregivers, multivariate models have shown that the mental 
HRQoL is lower, aside from those who report suffering 
from anxiety and/or depression, amongst those who spend 
a greater number of hours with the patient. Although CART 
models are generally used to “predict”, we found them useful 
in our study because there were many possible factors that 
could explain HRQoL, and traditional statistical methods 
are poorly suited for this sort of multiple comparison. 
Table 3 hRQoL (summary scales) of Ms patients and their 
caregivers
n Mean (SD) 95% CI Min Max
Patients
   sF-36 Physical health 
summary scale
696 39.85 (10.36) 39.08–40.62 14.36 63.66
    sF-36 Mental health 
summary scale
696 44.39 (12.02) 43.49–45.28 8.72 68.62
Caregivers
    sF-12 Physical health 
summary scale
522 49.63 (10.05) 48.77–50.49 18.10 66.44
    sF-12 Mental health 
summary scale
522 46.41 (10.66) 45.49–47.32 12.40 64.42
Abbreviations: hRQoL, health-related quality of life; n, sample size; sD, standard 
deviation; CI, confidence interval; Min, minimum value; Max, maximum value.
35
40
45
50
55
60
65
Patient SF-36 physical
health summary scale
Patient SF-36 mental   
health summary scale
Caregiver SF-12 physical
health summary scale
Caregiver SF-12 mental
health summary scale
Norm →
(General population)
Poorest 
HRQoL
Best 
HRQoL
Figure 1 interpretation of physical and mental health summary scales of Ms patients and their caregivers.
Notes: Vertical lines on each bar represent their 95% confidence intervals (see Table 3 for exact values). If they are not including the value of the norm, the difference 
between the study sample and the general population is statistically significant.Patient Preference and Adherence 2009:3 318
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Table 4 Family caregivers’ psychological well-being according to 
ghQ-12
Women Men Total sample
no psychological 
distress
196 (70.5%) 203 (75.7%) 399 (73.1%)
Probable psychological 
distress
82 (29.5%)* 65 (24.3%) 147 (26.9%)
Notes: Definition of probable distress: GHQ-12  3; *Statistically significant 
differences between male and female caregivers.
< Gral P: (360) 51.7%
= Gral P: (330) 47.4%
> Gral P: (6)     0.9%
n = 696
EDSS score
p < 0.0001
CHI2 = 110.73; DF = 4
0
to
2.5
3
to
6
6.5
to
9
< Gral P: (93)   29.6%
= Gral P: (216) 68.8%
> Gral P: (5)     1.6%
n = 314
Chronic co-morbidity
p = 0.000303
CHI2 = 28.3; DF = 4
0 1
2
3
to
8 < Gral P: (21)   16.8%
= Gral P: (102) 81.6%
> Gral P: (2)     1.6%
n = 125
< Gral P: (36) 30.0%
= Gral P: (82) 68.3%
> Gral P: (2)   1.7%
n = 120
< Gral P: (35) 53.8%
= Gral P: (29) 44.6%
> Gral P: (1)   1.5%
n = 65
< Gral P: (140) 63.9%
= Gral P: (78)   35.6%
> Gral P: (1)     0.5%
n = 219
Chronic co-morbidity
p = 0.000067
CHI2 = 23.61; DF = 2
0 1
to
9 < Gral P: (15) 33.3%
= Gral P: (30) 66.7%
> Gral P: (0)   0.0%
n = 45
< Gral P: (124) 71.7%
= Gral P: (48)   27.7%
> Gral P: (1)     0.6%
n = 173
MS treatment
p = 0.001395
CHI2 = 17.73; DF = 4
No treatment (21) 
Not selective Immuno suppressor (8)
Interferon-beta-1b (48)
Interferon-beta-1a (16)
Interferon-beta (no specified) (14)
Immuno globulins (2)
Others, not changing 
disease course (16) 
< Gral P: (27) 93.1%
= Gral P: (2)   6.9%
> Gral P: (0)   0.0%
n = 29
< Gral P: (57) 73.1%
= Gral P: (21) 26.9%
> Gral P: (0)    0.0%
n = 78
< Gral P: (8) 44.4%
= Gral P: (9) 50.0%
> Gral P: (1)   5.6%
n =18
< Gral P: (55) 91.7%
= Gral P: (5)   8.3%
> Gral P: (0)   0.0%
n = 60
Figure 2 explanatory factors for the physical domain of hRQoL in patients with Ms (sF-36 Physical health summary scale).
Notes:  gral P, Proportion of patients presenting lower hRQoL (physical domain) than general population; = gral P, Proportion of patients presenting the same hRQoL 
(physical domain) than general population;  gral P, Proportion of patients presenting higher hRQoL (physical domain) than general population; in parentheses, number of 
patients included in each category.
Abbreviations: DF, degrees of freedom; hRQoL, health-related quality of life.
In addition, complex interactions exist between factors and 
CART enabled us to avoid making assumptions regarding 
underlying distribution of the variables and also to overcome 
the problem of having to adjust for certain variables (eg, for 
anxiety and depression, which could confuse the association 
between physical disability and HRQoL in the MS patients, as 
some authors have suggested).53 By this technique we could 
consider the different subgroups of patients (eg, according 
to level of physical disability or whether they reported suffer 
from anxiety or depression) in analyzing these variables’ 
relationship to HRQoL.
Regarding these models, it should be noted that their 
accuracy was higher than that of the linear multiple 
regression models that had been used previously.54 In the 
latter, accuracy (R2) was only higher than 25% in the case of 
physical HRQoL; however, with the CART, accuracy varied 
from 58% to 73%. The explanation can be found in the fact 
that regression implies the existence of a linear relationship, 
but there are many nonlinear relationships and discontinuities 
in the present study’s factors as other studies also found,42 
and these are precisely what linear regression fails to catch. 
Therefore, our study’s methodological contribution has been 
to present the data in such a way that we have been able to 
detect some of these discontinuities. Moreover, it is much 
simpler to interpret than the multivariate regression model, 
bearing in mind that clinicians, patients, and caregivers 
generally do not think in terms of probability, which is 
the output regression model yields, but, rather in terms of Patient Preference and Adherence 2009:3 319
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categories, such as higher risk or lower risk than general 
population.
At this point, we should comment on some of the present 
study’s limitations. The first is that, although we obtained our 
target sample number of patients, we failed to meet our target 
for family caregivers, because the enrolment process went 
on for more than three years, and it was difficult to continue 
the project due to time and resource limitations. However, 
the sample size achieved (n = 551), once we subtract the 5% 
of participants with missing values (n = 522), means only 
that the maximum tolerated error – maintaining a confidence 
level of 95% – was 0.04 instead of 0.035. Regarding the 
patients sample, if we take into account mean duration of MS 
(6.3 years), the median EDSS score (2.5), and the proportion 
of patients with secondary progressive MS (11%), we can 
think of a sample skewed towards recent disease. However, 
after three years of data gathering in nine centers that was 
the real picture we obtained and, actually, a milder clinical 
severity has been described in this region.15 Moreover, our 
data were within the published HRQoL score ranges.39–47
Another limitation involves the instruments we used. 
First, according to one study, the SF-36 mental health 
summary scale appear to overestimate mental health in people 
with MS,55 but it could have biased our results towards higher 
mental HRQoL, meaning that the actual mental HRQoL was 
still lower, which it wouldn’t have change our conclusion, 
rather strengthen it. Second, also concerning the SF-36, 
some authors have postulated that, since it is a generic 
instrument, it is not sensitive enough to measure HRQoL 
in MS patients because it fails to consider the illness’s 
specific symptoms, and especially, for the baseline effect 
(incapacity to discriminate amongst degrees of poor HRQoL) 
of the dimensions of mobility and physical functioning, 
and the ceiling effect (incapacity to discriminate amongst 
degrees of better HRQoL) of the dimensions of “pain” and 
“role limitations due to emotional problems” in patients 
with MS.56,57 However, the SF-36 physical and mental health 
summary scales have no baseline or ceiling effects.57
Finally, on the subject of limitations, it is important to 
always bear in mind that the associations found do not indicate 
< Gral P: (128) 24.5%
= Gral P: (388) 74.3%
> Gral P: (6)     1.1%
n = 522
Anxiety (F)
p < 0.0001
CHI2 = 75.79; DF = 2
No (433) Yes (84)
< Gral P: (75)  17.3%
= Gral P: (353) 81.5%
> Gral P: (5)     1.2%
n = 433
Depression (F)
p = 0.000874
CHI2 = 14.09; DF = 2
No (415) Yes (18)
< Gral P: (66)  15.9% 
= Gral P: (344) 82.9% 
> Gral P: (5)     1.2% 
415
Kind of relationship with the patient 
p = 0.009877
CHI2 = 20.12; DF = 4
Spouse (278) Mother (69)
Child (28)
Others(19)
Father (16)
< Gral P: (40) 14.4% 
= Gral P: (236) 84.9% 
> Gral P: (2)     0.7% 
278
< Gral P: (25) 25.8% 
= Gral P: (71) 73.2% 
> Gral P: (1)    1.0% 
97
< P Gral: (0)    0.0%
= P Gral: (33) 94.3%
> P Gral: (2)    5.7%
35
< Gral P: (9) 50.0%
= Gral P: (9) 50.0%
> Gral P: (0)   0.0%
18
< Gral P: (52) 61.9%
= Gral P: (31) 36.9%
> Gral P: (1)    1.2%
n = 84
Hours/day in physically helping the patient
P = 0.024479
CHI2 = 7.42; DF = 2
(0,1.5) (1.5,4.5) (4.5,24)
< Gral P: (4)  30.8% 
= Gral P: (9)  69.2%
> Gral P: (0)    0.0% 
13
< Gral P: (12) 63.2%
= Gral P: (7)  36.8%
> Gral P: (0)    0.0%
19
< Gral P: (19) 76.0% 
= Gral P: (6)   24.0% 
> Gral P: (0)    0.0% 
25
Figure 3 explanatory factors for the mental domain of hRQoL in family caregivers (sF-12 Mental health summary scale).
Notes:  gral P, Proportion of patients presenting lower hRQoL (mental domain) than general population; = gral P, Proportion of patients presenting the same hRQoL 
(mental domain) than general population;  gral P, Proportion of patients presenting higher hRQoL (mental domain) than general population; in parentheses, number of 
caregivers included in each category.
Abbreviations: DF, degrees of freedom; hRQoL, health-related quality of life.Patient Preference and Adherence 2009:3 320
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causality, but only statistical association, and that, above all, 
since this is a cross-sectional study, we cannot determine 
precisely the direction of this association. However, the 
approximation through multivariate analysis carried out for 
the present study serves as a first step in order to then, in the 
future, confirm findings in a longitudinal study.
Conclusions
Our results enable us to conclude that in Catalonia (Southern 
Europe) the HRQoL of patients with MS, as well as their 
family caregivers, is indeed notably affected, compared with the 
HRQoL of the general population, and that women (whether 
patients or family caregivers) are more affected than men 
insofar as the mental domain of their HRQoL is concerned. 
Moreover, even in a region where family social support is 
more usual than in other areas, and therefore, caregiving role 
is present in most families, caregivers have a HRQoL closer to 
population with chronic illness than to general population.
This study is the first of its kind in a Catalan population to 
describe the HRQoL of patients with MS and their caregivers, 
and to assess the relative importance of individual factors 
to the physical and mental domains of the HRQoL. CART 
analysis is useful for explaining the different discontinuities 
of possible factors explaining the HRQoL of MS patients and 
their caregivers. According to this analysis, the factors able to 
explain a lower HRQoL are varied, and although in the case of 
patients the most relevant ones were clinically related, in the 
case of their caregivers, social factors as employment status or 
indirect impact of MS as time spent caring for patients, also 
explained a poor HRQoL. Looking at all of these factors, the 
implications to be derived from them are mainly research-
oriented: findings yielded by the present study need to be 
further examined using longitudinal designs, so that we may 
someday intervene in the factors that impact on HRQoL and, 
in the field of health services research, study how to better 
cope with the indirect impact (ie, on family caregivers) of 
chronic neurodegenerative illness.
Acknowledgments
Our thanks to all MS patients and their family caregivers 
who took part in this study. We would also like to thank the 
professionals who participated in the study: David Genís and 
Pepi López, Hospital Josep Trueta (Girona); Enric Bufill, 
Hospital General de Vic; Miquel Aguilar, Maite Olivella and 
Anna Suñer, Hospital Mútua de Terrassa; Miquel Marco, 
Consorci Hospitalari Parc Taulí (Sabadell); Domingo Escudero 
and M. Mataró Hospital Germans Trias i Pujol (Badalona); 
Josep Mª Grau Veciana, Hospital de Sant Pau (Barcelona); 
Xavier Montalbán and Cecília Borràs, Hospital Vall d’Hebron 
(Barcelona); Francesc X. Graus and Albert Sáez, Hospital Clínic 
(Barcelona); Txomin Arbizu, Hospital Universitari de Bellvitge; 
and Ingrid Galán, Montserrat Roig and Carme Oñó Hospital de 
Dia de la Fundació Esclerosi Múltiple (Barcelona).
This project was funded by the Instituto de Salud Carlos 
III of the Spanish Government, Fundación MAPFRE, and 
Fundació La Marató de TV3 (Catalan Telethon Foundation).
References
  1.  Neumann H. Molecular mechanisms of axonal damage in inflammatory 
central nervous system diseases. Curr Opin Neurol. 2003;16(3):267–273.
  2.  World Health Organization, Multiple Sclerosis International Federation. 
Atlas: Multiple Sclerosis Resources in the World 2008. Geneva, Switzerland: 
World Health Organization; 2008. Available from: http://www.who.int/
mental_health/neurology/en/. Accessed on August 10, 2009.
  3.  Kesselring J. Symptomatology. In: Kesselring J, editor. Multiple Sclerosis. 
Cambridge, UK: Cambridge University Press; 1997. p. 71–86.
  4.  Joy JE, Johnston BR. Multiple Sclerosis. Current Status and Strategies 
for the Future. Washington DC: National Academy Press; 2001.
  5.  Fayers PM, Machin D. Quality of life. Assessment, Analysis and 
Interpretation. West Sussex, UK: John Wiley & Sons Ltd; 2000.
  6.  Viischedijk MA, Uitdehaag BM, Klein M, et al. Value of health-related 
quality of life to predict disability course in multiple sclerosis. 
Neurology. 2004;63(11):2046–2050.
  7.  Nortvedt MW, Riise T. The use of quality of life measures in multiple 
sclerosis research. Mult Scler. 2003;9(1):63–72.
  8.  Benito-León J, Morales JM, Rivera-Navarro J, Mitchell AJ. A review 
about the impact of multiple sclerosis on health-related quality of life. 
Disabil Rehabil. 2003;25(23):1291–1303.
  9.  McKeown LP, Porter-Armstrong AP, Baxter GD. The needs and 
experiences of caregivers of individuals with multiple sclerosis: 
a systematic review. Clin Rehabil. 2003;17(3):234–248.
10.  Amato MP, Ponziani G, Rossi F, Liedl CL, Stefanile C, Rossi L. Quality 
of life in multiple sclerosis: the impact of depression, fatigue and 
disability. Mult Scler. 2001;7(5):340–344.
11.  Janardhan V , Bakshi R. Quality of life in patients with multiple sclerosis: 
the impact of fatigue and depression. J Neurol Sci. 2002;205(1):51–58.
12.  Pittion-Vouyovitch S, Debouverie M, Guillemin F, Vandenberghe N, 
Anxionnat R, Vespignani H. Fatigue in multiple sclerosis is related to disability, 
depression and quality of life. J Neurol Sci. 2006;243(1–2):39–45.
13.  Kalia LV , O’Connor PW. Severity of chronic pain and its relationship to 
quality of life in multiple sclerosis. Mult Scler. 2005;11(3):322–327.
14.  Nortvedt MW, Riise T, Myhr KM, Landtblom AM, Bakke A, Nyland HI. 
Reduced quality of life among multiple sclerosis patients with sexual 
disturbance and bladder dysfunction. Mult Scler. 2001;7(4):231–235.
15.  Bufill E, Blesa R, Galan I, Dean G. Prevalence of multiple sclerosis in 
the region of Osona, Catalonia, northern Spain. J Neurol Neurosurg 
Psychiatry. 1995;58(5):577–581.
16.  Naldini M. The Family in the Mediterranean Welfare States. London, 
UK: Frank Cass; 2003.
17.  Poser CM, Paty DW, Scheinberg LC, et al. New diagnostic criteria 
for multiple sclerosis: guidelines for research protocols. Ann Neurol. 
1983;13(3):227–231.
18.  Thompson AJ, Montalban X, Barkhof F, et al. Diagnostic criteria for 
primary progressive multiple sclerosis: a position paper. Ann Neurol. 
2000;47(6):831–835.
19.  Ware JE Jr, Gandek B. Overview of the SF-36 Health Survey and the 
International Quality of Life Assessment (IQOLA) Project. J Clin 
Epidemiol. 1998;51(11):903–912.
20.  Ware J Jr, Kosinski M, Keller SD.  A 12-Item Short-Form Health 
Survey. Construction of scales and preliminary tests of reliability and 
validity. Med Care. 1996;34(3):220–233.Patient Preference and Adherence 2009:3
Patient Preference and Adherence
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/patient-preference-and-adherence-journal
Patient Preference and Adherence is an international, peer-reviewed, 
open access journal that focusing on the growing importance of patient 
preference and adherence throughout the therapeutic continuum. Patient 
satisfaction, acceptability, quality of life, compliance, persistence and 
their role in developing new therapeutic modalities and compounds to 
optimize clinical outcomes for existing disease states are major areas of 
interest. This journal has been accepted for indexing on PubMed Central. 
The manuscript management system is completely online and includes a 
very quick and fair peer-review system. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
321
Multiple sclerosis and health-related quality of life Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
21.  Goldberg DP, Williams P. A User’s Guide to the General Health 
Questionnaire. Windsor, UK: NFER-Nelson; 1988.
22.  Alonso J, Prieto L, Antó JM. La versión española del SF-36 Health 
Survey (Cuestionario de Salud SF-36): un instrumento para la medida 
de los resultados clínicos. Med Clin (Barc). 1995;104(20):771–776.
23.  Muñoz PE, Vázquez-Barquero JL, Rodríguez F, Pastrana E, Varo J. 
Adaptación española del General Health Questionnaire (GHQ) de DP 
Goldberg. Arch Neurobiol. 1979;42:139–158.
24.  Rajmil L, Gispert R, Roset M, Muñoz PE, Segura A. Equipo de la 
Encuesta de Salud de Cataluña. Prevalencia de trastornos mentales en 
la población general de Cataluña. Gac Sanit. 1998;12(4):153–159.
25.  Alonso J, Regidor E, Barrio G, Prieto L, Rodríguez C, De la Fuente L. 
Valores poblacionales de referencia de la versión española del cues-
tionario de salud SF-36. Med Clin (Barc). 1998;111(11):410–416.
26.  Ware JE Jr. SF-36® Health Survey Update [homepage on the Internet]. 
Lincoln, RI: QualityMetric Inc; updated 2003 Set 11. Available from: 
http://www.sf-36.org/tools/sf36.shtml. Accessed on August 10, 2009.
27.  Vilagut G, Valderas JM, Ferrer M, Garin O, López-García E, Alonso J. 
Interpretación de los cuestionarios de salud SF-36 y SF-12 en España: 
components físico y mental. Med Clin (Barc). 2008;130(19): 
726–735.
28.  Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an 
expanded disability status scale (EDSS). Neurology. 1983;33(11): 
1444–1452.
29.  Brugulat P, Séculi E, Medina A, et al. Encuesta de Salud de Cataluña. 
Percepción de la salud, utilización y satisfacción con los servicios 
asistenciales desde la perspectiva de los ciudadanos. Med Clin (Barc). 
2003;121(Suppl 1):122–127.
30.  Breiman L, Friedman JH, Olshen RA, Stone CJ. Classification and 
Regression Trees. Boca Raton, FL: Chapman and Hall; 1984.
31.  Kobelt G, Berg J, Lindgren P, Fredrikson S, Jönsson B. Costs and quality 
of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg 
Psychiatry. 2006;77(8):918–926.
32.  Gottberg K, Einarsson U, Ytterberg C, et al. Health-related quality of 
life in a population-based sample of people with multiple sclerosis in 
Stockholm County. Mult Scler. 2006;12(5):605–612.
33.  Spain LA, Tubridy N, Kilpatrick TJ, Adams SJ, Holmes ACN. Illness 
perception and health-related quality of life in multiple sclerosis. Acta 
Neurol Scand. 2007;116(5):293–299.
34.  Jenkinson C, Layte R. Development and testing of the UK SF-12 
(short form health survey). J Health Serv Res Policy. 1997;2(1): 
14–18.
35.  Sugar CA, Sturm R, Lee TT, et al. Empirically defined health states 
for depression from the SF-12. Health Serv Res. 1998;33(4 Pt 1): 
911–928.
36.  Solari A, Ferrari G, Radice D. A longitudinal survey of self-assessed 
health trends in a community cohort of people with multiple sclerosis 
and their significant others. J Neurol Sci. 2006;243(1–2):13–20.
37.  Khan F, Pallant J, Brand C. Caregiver strain and factors associated with 
caregiver self efficacy and quality of life in a community cohort with 
multiple sclerosis. Disabil Rehabil. 2007;29(16):1241–1250.
38.  Alshubaili AF, Ohaeri JU,  Awadalla AW, Mabrouk AA. Family caregiver 
quality of life in multiple sclerosis among Kuwaitis: a controlled study. 
BMC Health Serv Res. 2008;8:206.
39.  The Canadian Burden of illness Study Group. Burden of illness of 
multiple sclerosis: Part II: Quality of life. Can J Neurol Sci. 1998;25(1): 
31–38.
40.  Forbes A, While A, Mathes L, Griffiths P. Health problems and 
health-related quality of life in people with multiple sclerosis. Clin 
Rehabil. 2006;20(1):67–78.
41.  Vermersch P, de Seze J, Delisse B, Lemaire S, Stojkovic T. Quality of life 
in multiple sclerosis: influence of interferon-β1a (Avonex®) treatment. 
Mult Scler. 2002;8(5):377–381.
42.  Miller A, Dishon S. Health-related quality of life in multiple sclerosis: 
The impact of disability, gender and employment status. Qual Life Res. 
2006;15(2):259–271.
43.  Patti F, Russo P, Pappalardo A, Macchia F, Civalleri L, Paolillo A; for 
the FAMS study group. Predictors of quality of life among patients 
with multiple sclerosis: An Italian cross-sectional study. J Neurol Sci. 
2007;252(2):121–129.
44.  Nortvedt MW, Riise T, Myhr KM, Nyland HI. Quality of life in multiple 
sclerosis: measuring the disease effects more broadly. Neurology. 
1999;53(5):1098–1103.
45.  Morales Rde R, Morales Nde M, Rocha FC, Fenelon SB, Pinto Rde M, 
Silva CH. Qualidade de vida em portadores de esclerose múltipla. Arq 
Neuropsiquiatr. 2007;65(2B):454–460.
46.  Arnoldus JHA, Killestein J, Pfennings LEMA, Jelles B, Uitdehaag BMJ, 
Polman CH. Quality of life during the first 6 months of interferon-β 
treatment in patients with MS. Mult Scler. 2000;6(5):338–342.
47.  Pittock SJ, Mayr WT, McClelland RL, et al. Quality of life is favorable 
for most patients with multiple sclerosis: a population-based cohort 
study. Arch Neurol. 2004;61(5):679–686.
48.  Patti F, Cacopardo M, Palermo F, et al. Health-related quality of life and 
depression in an Italian sample of multiple sclerosis patients. J Neurol 
Sci. 2003;211(1–2):55–62.
49.  Putzki N, Fischer J, Gottwald K, et al. Quality of life in 1000 patients 
with early relapsing–remitting multiple sclerosis. Eur J Neurol. 
2009;16(6):713–720.
50.  Navarro X, Bagunyà J, Galán I, et al. Registro de esclerosis múltiple 
en Cataluña. Evolución 1988–1993. Rev Neurol. 1994;22:391–396.
51.  Rivera-Navarro J, Morales-González JM, Benito-León J; Madrid 
Demyelinating Diseases Group (GEDMA). Informal caregiving in 
multiple sclerosis patients: data from the Madrid Demyelinating Disease 
Group study. Disabil Rehabil. 2003;25(18):1057–1064.
52.  Gregory RJ, Disler P. Caregivers of people with multiple sclerosis: 
a survey in New Zealand. Rehabil Nurs. 1996;21(1):31–37.
53.  Janssens AC, van Doorn PA, de Boer JB, et al. Anxiety and depression 
influence the relation between disability status and quality of life in 
multiple sclerosis. Mult Scler. 2003;9(4):397–403.
54.  Aymerich M. Impacte de l’esclerosi múltiple en la qualitat de vida 
relacionada amb la salut dels malalts i llurs familiars, i avaluació 
cost-efectivitat dels nous tractaments per aquesta malaltia. Estudi 
multicèntric a Catalunya. PhD Thesis. Cerdanyola del Vallès: Universitat 
Autònoma de Barcelona; 2002.
55.  Nortvedt M, Riise T, Myhr KM, Nyland HI. Performance of the 
SF-36, SF-12, and RAND-36 Summary Scales in a Multiple Sclerosis 
Population. Med Care. 2000;38(10):1022–1028.
56.  Vickrey BG, Hays RD, Genovese BJ, Myers LW, Ellison GW. Comparison 
of a generic to disease-targeted health-related quality-of-life measures 
for multiple sclerosis. J Clin Epidemiol. 1997;50(5):557–569.
57.  Freeman JA, Hobart JC, Langdon DW, Thompson AJ. Clinical appro-
priateness: a key factor in outcome measure selection: the 36 item short 
form health survey in multiple sclerosis. J Neurol Neurosurg Psychiatry. 
2000;68(2):150–156.